Repligen Co. (RGEN) Receives Average Rating of “Buy” from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have received an average rating of “Buy” from the eleven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $44.57.

RGEN has been the topic of several research analyst reports. BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Citigroup initiated coverage on Repligen in a research note on Friday, December 8th. They set a “buy” rating and a $45.00 target price on the stock. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research note on Thursday, October 5th. CL King initiated coverage on Repligen in a research note on Monday, November 13th. They set a “buy” rating and a $41.00 target price on the stock. Finally, TheStreet downgraded Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th.

Repligen (RGEN) opened at $36.89 on Friday. Repligen has a fifty-two week low of $28.61 and a fifty-two week high of $46.81. The stock has a market capitalization of $1,610.00, a price-to-earnings ratio of 62.53, a PEG ratio of 2.06 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The business had revenue of $36.58 million for the quarter, compared to the consensus estimate of $35.69 million. During the same period last year, the business posted $0.08 EPS. The business’s revenue was up 48.2% compared to the same quarter last year. analysts expect that Repligen will post 0.61 EPS for the current year.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of Repligen stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the completion of the sale, the vice president now owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 8,970 shares of Repligen stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the sale, the chief executive officer now directly owns 83,613 shares of the company’s stock, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. lifted its holdings in shares of Repligen by 162.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 3,491 shares during the period. NBW Capital LLC lifted its holdings in shares of Repligen by 93.8% in the 2nd quarter. NBW Capital LLC now owns 43,909 shares of the biotechnology company’s stock valued at $1,820,000 after buying an additional 21,254 shares during the period. PointState Capital LP acquired a new position in shares of Repligen in the 2nd quarter valued at about $11,984,000. Palisade Capital Management LLC NJ lifted its holdings in shares of Repligen by 4.5% in the 3rd quarter. Palisade Capital Management LLC NJ now owns 658,979 shares of the biotechnology company’s stock valued at $25,252,000 after buying an additional 28,646 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of Repligen in the 3rd quarter valued at about $3,349,000. 82.48% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Repligen Co. (RGEN) Receives Average Rating of “Buy” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/27/repligen-co-rgen-receives-average-rating-of-buy-from-analysts.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply